Antiretroviral therapy, interferon sensitivity, and virologic setpoint in human immunodeficiency virus/hepatitis C virus coinfected patients.

@article{Balagopal2014AntiretroviralTI,
  title={Antiretroviral therapy, interferon sensitivity, and virologic setpoint in human immunodeficiency virus/hepatitis C virus coinfected patients.},
  author={Ashwin Balagopal and Abraham J. Kandathil and Yvonne Higgins and Jonathan Wood and Justin Richer and Jeffrey J. Quinn and Lois Eldred and Zhiping Li and Stuart C. Ray and Mark S Sulkowski and David L. Thomas},
  journal={Hepatology},
  year={2014},
  volume={60 2},
  pages={
          477-86
        }
}

• Ashwin Balagopal, Abraham J. Kandathil, +8 authors David L. Thomas
• Published in Hepatology 2014
• DOI:10.1002/hep.27158

UNLABELLED Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) cause substantial mortality, especially in persons chronically infected with both viruses. HIV infection raises plasma HCV RNA levels and diminishes the response to exogenous alpha interferon (IFN). The degree to which antiretroviral therapy (ART) control of infection overcomes these HIV effects is unknown. Participants with HIV-HCV coinfection were enrolled in a trial to measure HCV viral kinetics after IFN… CONTINUE READING

View on PubMed

Open Access

Save to Library

Create Alert

Cite